Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

Hanan Polansky, Edan Itzkovitz, Adrian Javaherian, Hanan Polansky, Edan Itzkovitz, Adrian Javaherian

Abstract

Background: We conducted a clinical study that tested the effect of suppressive treatment with the botanical product Gene-Eden-VIR/Novirin on genital herpes. Our previous paper showed that the treatment decreased the number of genital herpes outbreaks without any side effects. It also showed that the clinical effects of Gene-Eden-VIR/Novirin are mostly better than those reported in the studies that tested acyclovir, valacyclovir, and famciclovir. The current paper reports the effect of suppressive treatment with Gene-Eden-VIR/Novirin on the duration of outbreaks, in severe and mild genital herpes cases.

Methods: The framework was a retrospective chart review. The population included 137 participants. The treatment was 1-4 capsules per day. The duration of treatment was 2-48 months. The study included three controls: baseline, no-treatment, and dose-response.

Results: The treatment decreased the duration of outbreaks in 87 % of participants and decreased the mean duration of outbreaks from 8.77 days and 6.7 days in the control groups to 2.87 days in the treatment group (P < 0.001, both groups). All participants reported no adverse experiences.

Conclusions: This paper shows that suppressive treatment with Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks, in both severe and mild cases, without any side effects. Based on the results reported in this and our previous paper, we recommend suppressive treatment with Gene-Eden-VIR/Novirin as a natural alternative to both suppressive and episodic treatments with current drugs, in both severe and mild genital herpes cases. Trial registration ClinicalTrials.gov NCT02715752 Registered 17 March 2016 Retrospectively Registered.

Keywords: Acyclovir; Famciclovir; Genital herpes; Natural treatment; Outbreaks; Valacyclovir.

Figures

Fig. 1
Fig. 1
Graph showing the percentage of participants versus duration of outbreaks in the treatment, pre-treatment and no-treatment groups

References

    1. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-group, randomized, double-blind clinical trial. Br J Dermatol. 2001;144(4):818–824. doi: 10.1046/j.1365-2133.2001.04139.x.
    1. LeCleach L, Trinquart L, Do G, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev. 2014;8:CD009036.
    1. Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N Engl J Med. 2004;350(19):1970–1977. doi: 10.1056/NEJMcp023065.
    1. Johnston C, Corey L. Current concepts for genital Herpes Simplex Virus Infection: diagnostics and pathogenesis of genital tract shedding. Clin Microbiol Rev. 2016;29(1):149–161. doi: 10.1128/CMR.00043-15.
    1. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238–246. doi: 10.1016/j.jaad.2007.02.008.
    1. Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc) 2014;79(13):1635–1652. doi: 10.1134/S0006297914130124.
    1. Mattison HR, Reichman RC, Benedetti J, et al. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. Am J Med. 1988;85(2A):20–25.
    1. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20. doi: 10.1056/NEJMoa035144.
    1. Yavuz BB, Cankurtaran M, Halil M, Dagli N, Kirkpantur A. Renal dysfunction after oral acyclovir treatment in a geriatric woman: a case report. Scand J Infect Dis. 2005;37(8):611–613.
    1. Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G. Rapidly progressive acute renal failure due to acyclovir: a case report and review of the literature. Am J Kidney Dis. 1993;22(4):611–615. doi: 10.1016/S0272-6386(12)80939-5.
    1. Berry L, Venkatesan P. Aciclovir-induced neurotoxicity: utility of CSF and serum CMMG levels in diagnosis. J Clin Virol. 2014;61(4):608–610. doi: 10.1016/j.jcv.2014.09.001.
    1. Lam NN, Weir MA, Yao Z, et al. Risk of acute kidney injury from oral acyclovir: a population-based study. Am J Kidney Dis. 2013;61(5):723–729. doi: 10.1053/j.ajkd.2012.12.008.
    1. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA. 1984;251(16):2103–2107. doi: 10.1001/jama.1984.03340400031020.
    1. Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012;205(7):1100–1110. doi: 10.1093/infdis/jis019.
    1. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42(1):8–13. doi: 10.1086/498521.
    1. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168:1137. doi: 10.1001/archinte.168.11.1137.
    1. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International valaciclovir HSV study group. J Infect Dis. 1998;178(3):603–610. doi: 10.1086/515385.
    1. Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, Tyring SK. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative famciclovir genital herpes research group. Arch Intern Med. 1997;157(3):343–349. doi: 10.1001/archinte.1997.00440240109016.
    1. Polansky H, Javaherian A. 3-Ecosystems: microRNAs, receptors, and latent viruses: some insights biology can gain from economic theory. Front Microbiol. 2016;7:369. doi: 10.3389/fmicb.2016.00369.
    1. Polansky H, Javaherian A. Commentary: the unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta. Front Cell Infect Microbiol. 2015;5:66. doi: 10.3389/fcimb.2015.00066.
    1. Polansky H. Microcompetition with foreign DNA and the origin of chronic disease. Rochester: CBCD Publishing; 2003.
    1. Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4:1–8. doi: 10.4236/pp.2013.46A001.
    1. Polansky H, Itzkovitz E. Gene-Eden-VIR decreased physical and mental fatigue in a post marketing clinical study that followed FDA guidelines; results support microcompetition theory. Pharmacol Pharm. 2014;5:280–290. doi: 10.4236/pp.2014.53035.
    1. Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016;10:2713–2722. doi: 10.2147/DDDT.S112852.
    1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry, E 10 Choice of Control Group and Related Issues in Clinical Trials,” 2001
    1. Calvert M, Kyte D, Duffy H, et al. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS ONE. 2014;9(10):e110216. doi: 10.1371/journal.pone.0110216.
    1. Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from (2007–2013) Contemp Clin Trials. 2015;43:1–9. doi: 10.1016/j.cct.2015.04.004.
    1. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25(6):535–552. doi: 10.1016/j.cct.2004.09.003.
    1. Albrecht MA. Clinical features (2015). In: Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection, UpToDate.
    1. Romanowski B, Marina RB, Roberts JN. Valtrex HS230017 study group. patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis. 2003;30(3):226–231. doi: 10.1097/00007435-200303000-00010.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj